- April 7, 2009
- In product Liability
According to a recent Food and Drug Administration (FDA) press release, Watson Pharmaceuticals, Inc. has announced a voluntary recall of one lot of Propafenone HCL 225 mg tablets, an anti-arrhythmia drug. The tablets are being voluntarily recalled because some tablets may contain higher levels of the drug than is specified on the product labeling.
This is a serious issue. Changes in the dosage of Propafenone may affect some patients more than others. The FDA press release mentions irregular heartbeat or low blood pressure as potential side effects in sensitive patients. Those taking the drug are encouraged to review the lot number and expiration date to determine if their medication is subject to the recall.
- Affected Product: Propafenone HCL 225 mg tablets sold in 100-count bottles
- Lot Number: 112680A
- Expiration Date: July 31, 2010
Although Watson Pharmaceuticals, Inc. is voluntarily recalling the product from general use, this action does not necessarily shield the company from liability should someone taking the anti-arrhythmia drug suffer serious harm from taking the incorrect dosage. The company is simply limiting the potential harm caused by the misdosage. The company’s self-interest in this case aligns with the interests of the general public, one of the intended benefits of a civil court system that allows pharmaceutical litigation to protect the interests of consumers.
If you have any questions regarding pharmaceutical liability lawsuits, or how liability and negligence encourages ethical behavior at the corporate level, please contact the Los Angeles liability attorneys at the Law Offices of Samer Habbas.